Tia Lyles-Williams
Founder & CEO
1st Biotherapeutics
1STBIO develops novel therapeutics targeting neurodegenerative diseases, immuno-oncology, and rare diseases through a genomic-based target discovery platform. The company addresses significant unmet medical needs by transforming breakthrough scientific discoveries into effective medicines for patients.
- Biotechnology
Updated 7 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many neurodegenerative diseases, cancers, and rare diseases lack effective treatments due to the difficulty in identifying and validating novel drug targets. Traditional drug discovery methods often fail to translate breakthrough scientific discoveries into effective medicines for patients with these conditions.
Solution
1STBIO is developing a portfolio of drug candidates in neurodegenerative diseases, immuno-oncology, and rare diseases. The company utilizes a genomic-based target discovery platform to identify and validate novel therapeutic targets. By focusing on areas of significant unmet need, 1STBIO aims to transform breakthrough scientific discoveries into effective medicines for patients.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases, cancer, and rare diseases, as well as healthcare providers seeking innovative treatment options.
Features
- Genomic-based target discovery platform for identifying novel drug targets
- Focus on neurodegenerative diseases, immuno-oncology, and rare diseases
- Portfolio of drug candidates in development
- Expertise in drug development to translate scientific discoveries into medicines